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-carboxaAbstract In the present investigation we report herein the synthesis and neuroprotection assay of
3-substituted-N-aryl-6,7-dimethoxy-3a,4-dihydro-3H-indeno[1,2-c]pyrazole-2-carboxamide (4a–c).
The anticonvulsant activity and neuroprotection assay were done according to Antiepileptic Drug
Development Programme (ADD) protocol reported elsewhere. The compounds showed signiﬁcant
anticonvulsant and neuroprotective activities. The compound 4b showed neuroprotection activity
with 26.2 ± 1.9% of total propidium iodide uptake at 100 lM and IC50 of the compound was cal-
culated using dose response curve by probit analysis and was found to be 159.20 ± 1.21 lM.
ª 2013 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Despite the development of newer antiepileptic drugs (AEDs),
epilepsy is still the 3rd most devastating neurological disorder
and nearly 1–2% of the world’s population is afﬂicted with this
disorder (Global Campaign Against Epilepsy, 2001; White,
2003). Treatment of epilepsy with the available AEDs is inad-
equate and associated with toxic and idiosyncratic effects
(Duncan, 2002; Dimmock et al., 1995). Today anticonvulsant
agents having neuroprotective actions have received consider-
able attention in the treatment of epilepsy since epileptic2335120.
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mide analogues. Arabian Journal oseizure and neurodegeneration share the common aspects of
their underlying pathophysiology and some AEDs are equally
effective neuroprotectives (Stanisaw et al., 2007). Phenytoin,
topiramate, and zonisamide are examples of AEDs, which
are also used as neuroprotective agents (Jain, 2011). It has
been reported that neurodegeneration is the major neurobio-
logical abnormality in epileptic brain (Naegele, 2007). Neuro-
protection also aims to prevent or slow disease progression
and secondary injuries by halting or at least slowing the loss
of neuron (Seidl and Potashkin, 2011), and neuroprotective
agents are used in an attempt to save ischaemic neurons in
the brain for irreversible injury (Green, 2004). The develop-
ment of a newer drug with increase seizure control, increased
tolerability, better safety and pharmacokinetic properties,
and with neuroprotective action might be a potential approach
to reduce the number of epileptic cases. Earlier we have re-
ported the anticonvulsant activity of pyrazoline analogues
(Ahsan et al., 2012, 2013). Nowadays organotypic hippocam-
pal brain slice cultures have been gaining importance as anier B.V. All rights reserved.
europrotection assay of 3-substituted-N-aryl-6,7-dimethoxy-3a,4-dihy-
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2 M.J. Ahsanearly stage drug screening tool in the neuroprotection arena
(Norenberg et al., 2005). We can evaluate the ability of novel
compounds to prevent excitotoxic cell death when these com-
pounds are added either in conjunction with, or following, the
treatment with agents that induce excitotoxic cell death. The
aim of the present study was to investigate the anticonvulsant
and neuroprotective activities of the synthesized pyrazoline
compounds.O
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Scheme 1 Protocol for the synthesis 3-substituted-N-aryl-6,7-
dimethoxy-3a,4-dihydro-3H-indeno[1,2-c]pyrazole-2-carboxamide
analogues (4a–c).2. Experimental
2.1. Chemistry
The entire chemicals were supplied by E. Merck (Germany)
and S.D. Fine Chemicals (India). Melting points were deter-
mined by open tube capillary method and are uncorrected.
Purity of the compounds was checked on TLC plates (silica
gel G) using eluants benzene–acetone (9:1), the spots were lo-
cated under iodine vapours or UV light. IR spectra were ob-
tained on a Schimadzu 8201 PC, FT-IR spectrometer (KBr
pellets). 1H NMR spectra were recorded on a Bruker AC
300 MHz spectrometer using TMS as internal standard in
DMSO. Mass spectra were recorded on a Bruker Esquire
LCMS using ESI and elemental analyses were performed on
Perkin-Elmer 2400 Elemental Analyzer.
2.2. General method for the synthesis of 2-substituted-5,6-
dimethoxy-2,3-dihydro-1H-indene-1-one derivatives (3a–c)
5,6-Dimethoxy-2,3-dihydro-1H-inden-1-one (1) (0.001 mol)
with appropriate aromatic aldehyde (2a–c) (0.001 mol) in di-
luted methanolic sodium hydroxide solution was stirred under
room temperature for 4 h. The resulting solution was allowed
to stand overnight and then the reaction mixture was poured
into cold water and neutralized with dilute HCl. The solid
was ﬁltered, dried and recrystallized with ethanol furnished
the 2-substituted-5,6-dimethoxy-2,3-dihydro-1H-indene-1-one
(3a–c) (Ahsan et al., 2011).
2.3. General method for the synthesis of 3a,4-dihydro-3H-
indeno[1,2-c]pyrazole-2-carboxamide analogues (4a–c)
2-substituted-5,6-dimethoxy-2,3-dihydro-1H-indene-1-one
(3a–c) (0.01 mol) and substituted phenyl semicarbazide
(0.01 mol) in 20 ml glacial acetic acid were reﬂuxed for 12 h.
The excess solvent was removed under reduced pressure and
then the reaction mixture was poured into crushed ice. The so-
lid mass was ﬁltered, dried and recrystallized with ethanol to
furnish 3-substituted-N-aryl-6,7-dimethoxy-3a,4-dihydro-
3H-indeno[1,2-c]pyrazole-2-carboxamide (Ahsan et al., 2011).
2.3.1. 3-(3,4-Dimethoxyphenyl)-N-(3-choro-4-ﬂuorophenyl)-
6,7-dimethoxy-3a,4-dihydro-3H-indeno[1,2-c]pyrazole-2-
carboxamide (4a)
Yield 78%, m.p. 202 C, IR (KBr) cm1: 3331 (NH), 1680
(C‚O), 1561 (C‚N), 1157 (C–N), 789 (C–F), 765 (C–Cl);
1H NMR (300 MHz, DMSO-d6): d 3.18–3.22 (1H, m, CH),
3.31–3.33 (2H, d, J = 6.0 Hz, CH2), 3.81 (6H, s, OCH3),
3.83 (6H, s, OCH3), 4.01 (1H, d, J= 6.1 Hz, CH), 7.29–7.89Please cite this article in press as: Ahsan, M.J. Anticonvulsant activity and n
dro-3H-indeno[1,2-c]pyrazole-2-carboxamide analogues. Arabian Journal o(8H, m, Ar), 10.05 (1H, s, CONH); MS: m/z, M+ 525,
M++2 527.
2.3.2. 3-(Pyridin-4-yl)-N-(4-chlorophenyl)-6,7-dimethoxy-
3a,4-dihydro-3H-indeno[1,2-c]pyrazole-2-carboxamide (4b)
M.p. 116 C; yield 72% (Ahsan et al., 2011).
2.3.3. 3-(4-Fluorophenyl)-N-(4-chlorophenyl)-6,7-dimethoxy-
3a,4-dihydro-3H-indeno[1,2-c]pyrazole-2-carboxamide (4c)
M.p. 128 C; yield 70% (Ahsan et al., 2011).
2.4. Anticonvulsant screening
The anticonvulsant screening of the compound was done
according to the Antiepileptic Drug Development Programme
(ADD) protocol reported elsewhere (Swinyard et al., 1989;
White et al., 1995a,b; Dunham and Miya, 1957; Barton
et al., 2001; Toman et al., 1952).
2.5. In vitro hippocampal slice culture neuroprotection assay
The ‘‘Primary Screen Experiment’’ is a qualitative assessment
of the ability of a compound to prevent excitotoxic cell death
(Norenberg et al., 2005). Slice cultures were prepared as per the
reported method (Stoppini et al., 1991; Norenberg, 2004).
Sprague–Dawley rat pups (10–11 days) were anesthetized with
pentobarbital, sacriﬁced, and their brains rapidly removed and
placed on sterile ﬁlter paper. The brain was kept moist with
sterile ﬁltered dissection buffer. The brain was then bisected
sagitally and the brainstem removed, revealing the cortex
and underlying hippocampus. The tissue was then placed on
a McElwain tissue chopper plate and then sliced into 400 lm
thick sections. Slices were placed in a small petri dish and
the hippocampi were then separated under microscopic con-
trol. Sections were then transferred into a six well culture plate
containing a membrane insert (30 mm, Millipore). Each well
contained four slices and 1 ml of media contained: 50% Opti
MEM, 25% horse serum, 25% Hank’s balanced salt solution
and D-glucose (25 mM). The cultures were then placed in an
incubator (5% CO2, 95% O2) and maintained at 36 C. One
day prior to the experiment, the culture medium was replaced
with 1.0 ml of serum-free media containing neurobasaleuroprotection assay of 3-substituted-N-aryl-6,7-dimethoxy-3a,4-dihy-
f Chemistry (2013), http://dx.doi.org/10.1016/j.arabjc.2013.10.023
Table 2 Results of in vitro hippocampal slice culture neuroprotection assay (Test 76) of 3-substituted-N-aryl-6,7-dimethoxy-3a,4-
dihydro-3H-indeno[1,2-c]pyrazole-2-carboxamide analogues (4a–c).
Compound Excitotoxin Insult duration (h) Primary screen result
4a Kainic acid (KA) 4 No neuroprotection observed
4b Kainic acid (KA) 4 Neuroprotection observed
4c Kainic acid (KA) 4 No neuroprotection observed
Table 3 In vitro hippocampal slice culture neuroprotection assay of compound 4b.
Compound concentration (lM) No. of slices Total propidium iodide uptake (%) ± (S.E.M.)
0 16 51.4 ± 1.6
10 8 36.6 ± 2.8*
30 8 43.4 ± 2.7*
100 8 26.2 ± 1.9*
300 8 26.4 ± 1.5*
* Data is signiﬁcantly different from excitotoxin treatment alone, p< 0.05.
Figure 1 Experimental images and well description at (A) 20 lMKA, (B) 20 lMKA+ 10 lM compound 4b, (C) 20 lMKA+ 10 lM
compound 4b, (D) 20 lM KA, (E) 20 lM KA+ 100 lM compound 4b, (F) 20 lM KA+ 100 lM compound 4b.
Anticonvulsant activity and neuroprotection assay 3medium, 25 mM D-glucose, 1 mM L-glutamine and 2% B27
supplement. Organotypic hippocampal slice cultures were trea-
ted with N-methyl-D-aspartate (NMDA) or kainic acid (KA)
to induce neuronal cell death. Propidium iodide, a mem-
brane-impermeant compound, was included in all wells of
the culture plate. Dying cells have compromised cell mem-
branes, thus propidium iodide may diffuse into the cell, inter-
calate with DNA and ﬂuoresce and the intensity of the
propidium iodide ﬂuorescence is proportional to the amount
of cell death in the individual slices. Hippocampal slice cultures
were treated with the excitotoxin alone or as indicated above,
with the excitotoxin and either one or two investigational com-
pounds at the concentrations indicated. If neuroprotection oc-
curs as a consequence of the added compound, slice cultures
will have a visibly reduced ﬂuorescent intensity when com-
pared to the slice cultures that have been treated with the
excitotoxin alone.Please cite this article in press as: Ahsan, M.J. Anticonvulsant activity and n
dro-3H-indeno[1,2-c]pyrazole-2-carboxamide analogues. Arabian Journal o3. Results and discussion
3.1. Chemistry
The 3-substituted-N-aryl-6,7-dimethoxy-3a,4-dihydro-3H-inde-
no[1,2-c]pyrazole-2-carboxamide (4a–c) described in this study
was synthesized as per the reported method and is summarized
in Scheme 1 (Ahsan et al., 2011) and their physical constants
are described in Table 1. In the initial step equimolar mixtures
of 5,6-dimethoxy-2,3-dihydro-1H-inden-1-one (1) and aromatic
aldehydes (2a–c) in diluted methanolic sodium hydroxide
solution were stirred at room temperature giving 2-(4-pyridi-
nyl)-5,6-dimethoxy-2,3-dihydro-1H-indene-1-one (3a–c). In the
subsequent step 2-substituted-5,6-dimethoxy-2,3-dihydro-1H-in-
dene-1-onewas treatedwith appropriate substituted phenyl semi-
carbazides furnishing the title compound (4a–c). The substitutedeuroprotection assay of 3-substituted-N-aryl-6,7-dimethoxy-3a,4-dihy-
f Chemistry (2013), http://dx.doi.org/10.1016/j.arabjc.2013.10.023
Table 1 Physical constant of 3-substituted-N-aryl-6,7-dimethoxy-3a,4-dihydro-3H-indeno[1,2-c]pyrazole-2-carboxamide analogues
(4a–c)
N NO
O
Ar
1
N
Ar
2O
H
4a-c
.
Compound ADD No. Ar1 Ar2 Yield (%) M.p. (C)
4a 439066 3,4-Dimethoxyphenyl- 3-Chloro-4-ﬂuorophenyl- 78 202
4b 439068 4-Pyrinyl- 4-Chlorophenyl- 72 116
4c 439070 4-Fluorophenyl- 4-Chlorophenyl- 70 128
4 M.J. Ahsanphenyl semicarbazideswas synthesized as per the reportedmeth-
od (Amir et al., 2010). The yields of the compounds ranged from
70% to 78% after recrystallization with absolute ethanol. The
reactions were monitored by TLC using benzene–acetone (9:1)
as mobile phase and the purity of the compounds was checked
by elemental analysis and mass spectroscopy.
3.2. Anticonvulsant screening
The compound 4b showed protection against maximal electro-
shock induced seizure (MES) and subcutaneous metrazole
(scMET) induced seizure at 300 mg/kg dose at 0.5 and 4 h,
and 100% (4/4, 0.25 h), 75% (3/4, 1.0 h) and 50% (2/4,
0.5 h) protection in 6 Hz psychomotor seizure test devoid of
any neurotoxicity or toxicity. The compound 4b also showed
50% (2/4, 1.0 h) and 25% (1/4, 2.0 h) protection in MES
screen after oral administration in rat at dose 30 mg/kg with-
out any toxicity (Ahsan et al., 2013). The compound 4a
showed 50% (2/4, 0.5–1.0 h) and 25% (1/4, 2.0 h), while com-
pound 4c showed 100% (4/4, 0.25–0.5 h), 75% (3/4, 1.0 h) and
25% (1/4, 4.0 h) protection in 6 Hz psychomotor seizure test
(Ahsan et al., 2012).
3.3. In vitro hippocampal slice culture neuroprotection assay
The compounds 4a and 4c have not shown any neuroprotec-
tion activity excitotoxin against kainic acid (Table 2). In vitro
hippocampal slice culture neuroprotection assay of compound
4b showed that the percent of total propidium iodide uptake
was 51.4 ± 1.6 when hippocampal slice cultures were treated
with the excitotoxin kainic acid (KA) alone (20 lM). The per-
cent of total propidium iodide uptake was 36.6 ± 2.8,
43.4 ± 2.7, 26.2 ± 1.9 and 26.4 ± 1.5 when compound 4b
was added with KA at concentrations 10, 30, 100 and
300 lM respectively. The data are given in Table 3 which show
signiﬁcant neuroprotection of compound 4b when coapplied
with KA. The concentration–response curve was determined
using Probit analysis to determine the IC50. The IC50 of com-
pound 4b was found to be 159.20 ± 1.21 lM. The compound
4b attenuated KA-mediated cell death in organotypica hippo-
campal slice cultures is shown in Fig. 1. The intensity of the
propidium iodide ﬂuorescence reduced as the concentration
of the compound 4b increased.Please cite this article in press as: Ahsan, M.J. Anticonvulsant activity and n
dro-3H-indeno[1,2-c]pyrazole-2-carboxamide analogues. Arabian Journal o4. Conclusions
In summary compound 4b was found to be active and showed
protection against seizure in MES, scMET and 6 Hz psycho-
motor seizure test. The compound 4b also showed neuropro-
tection against in vitro hippocampal slice culture when
coapplied with KA. The pyrazoline derivative reported in this
study may provide valuable therapeutic intervention for the
treatment of epilepsy.
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